Company / Net Income
Cue Biopharma, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$26.6M
FY2025
5-year range
-$53.0M / -$26.6M
FY2021-FY2025
Trend
+34.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has increased for 3 consecutive years, from -$53M in FY2022 to -$27M in FY2025.
Based on SEC 10-K filings.
-$27M in FY2025.
Improved from -$51M to -$27M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Cue Biopharma, Inc.'s net income has grown for 3 consecutive years.
- In FY2025, net income increased 34.6% year-over-year.
- Peak net income was recorded in FY2018.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$26.6M | +34.6% |
| FY2024 | -$40.7M | +19.8% |
| FY2023 | -$50.7M | +4.3% |
| FY2022 | -$53.0M | -20.0% |
| FY2021 | -$44.2M | -20.3% |
| FY2020 | -$36.7M | +5.9% |
| FY2019 | -$39.0M | -67.8% |
| FY2018 | -$23.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026